OnKure Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -213.3% | – | – | – | – | – | – | – | – | – | – | |
| – | +909.3% | -65.2% | -2.0% | +4.7% | +301.3% | -65.9% | +0.0% | -3.8% | -1.0% | +0.5% | -7.4% | – | |
| – | -195.6% | – | +1,594.4% | -95.8% | +2,026.0% | +67.7% | +5.9% | +1.8% | +2.0% | -7.9% | +9.7% | – | |
| – | -4,402.6% | – | – | -90.6% | +1,739.2% | -110.5% | – | – | – | – | – | – | |
| – | +163.2% | -82.0% | +11.1% | +80.0% | +177.8% | -64.0% | -27.8% | -53.8% | +50.0% | -44.4% | -40.0% | – | |
| – | +36.5% | -100.0% | +11.1% | +80.0% | +251,983.3% | -100.0% | -27.8% | -53.8% | +50.0% | -44.4% | +197,300.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6,960.1% | – | +58,580.0% | -99.9% | +2,284,260.0% | -100.1% | -100.0% | – | – | +60,732.9% | -103.7% | – | |
| – | +582.9% | -158.6% | – | – | – | -128.2% | – | – | – | – | -119.2% | – | |
| – | – | -214.0% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.